At a glance
ClinicalIndex Comparison Record- ✓Idiopathic Parkinson Disease diagnosis by modified UK PD brain bank criteria
- ✓Hoehn and Yahr stages less than 3
- ✓Disease duration less than 3 years since diagnosis
- ✓Age 40-80 years
- ✕Currently on PD medications (levodopa, dopamine agonists, MAO-B inhibitors, amantadine, anticholinergics)
- ✕Expected to require PD medication within first 6 months
- ✕Any PD medication within 60 days prior to baseline
- ✕Previous PD medication use exceeding 60 days total duration
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Study in Parkinson Disease of Exercise Phase 3 Clinical Trial: SPARX3
In Brief
A clinical study evaluating Treadmill walking for Parkinson Disease. Currently recruiting, targeting 370 participants across 25 sites in 2 countries.
Signals
Detailed Summary
This study is a Phase 3 multi-site, randomized, evaluator-masked, study of endurance treadmill exercise on changes in the Movement Disorder Society-Unified Parkinson Disease Rating Scale (MDS-UPDRS) Part III score at 12 months among persons with early stage Parkinson disease. 370 participants will be randomly assigned to 2 groups: 1)60-65% HRmax or 2)80-85% HRmax 4 times per week. The primary objective is to test whether the progression of the signs of Parkinson's disease is attenuated at 12 months in among persons who have not initiated medication for Parkinson Disease (PD) when they perform high-intensity endurance treadmill exercise.
Study Details
Timeline
Interventions
Treadmill walking 4 days per week for 30 minutes in the target heart rate